



# Journal of Pharmaceutical and Biological Research

Journal Home Page: [www.pharmaresearchlibrary.com/jpbr](http://www.pharmaresearchlibrary.com/jpbr)



## Research Article

### Formulation, Development and In-Vitro studies of Sotalol - Gastro Retentive Floating tablets

K. Jacob Isaac\*, Bh. Sri Swetha, D. Raghava, K. Nageswara Rao

Department of Pharmaceutical Technology, K.G.R.L College of Pharmacy, Bhimavaram-534201, Andhra Pradesh, India

#### ABSTRACT

In the “present research work gastro retentive floating matrix formulation of Sotalol” by “using various hydrophilic polymers. “Among all the formulations” the formulations prepared by using Xanthan gum were “unable to produce desired drug release, they were unable to” retard “drug release up to 12” hours. The formulations prepared with Methocel K15 M retarded the drug “release up to 12 hours” in the concentration of 75 mg (ST3).The “formulations prepared with xanthan gum” were “unable to retarded the drug “release for more than 12 hours. Hence they were not considered”.

**Keywords:** Sotalol, Guar gum, Xanthum gum, HPMC K15 M and Floating tablets

#### ARTICLE INFO

##### Corresponding Author

K. Jacob Isaac

Department of Pharmaceutical Technology,  
K.G.R.L College of Pharmacy, Bhimavaram-534201,  
Andhra Pradesh, India.



Journal QR-Code

**ARTICLE HISTORY:** Received 5 July 2023, Accepted 10 Aug 2023, Available Online 2 Oct 2023

**Copyright©2023** Production and hosting by Journal of Pharmaceutical and Biological Research. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.

**Citation:** K. Jacob Isaac, et al. Formulation, Development and In-Vitro studies of Sotalol - Gastro Retentive Floating tablets. *J. Pharm. Bio. Res.*, 2023, 11(1): 39-43.

#### CONTENTS

1. Introduction . . . . .	39
2. Methodology. . . . .	40
3. Results and Discussion. . . . .	36
4. Conclusion . . . . .	42
5. References. . . . .	42

#### 1. Introduction

Floating systems or dynamically controlled systems are low density systems that have sufficiently buoyancy to flow over the gastric contents and remain “buoyant in the stomach without affecting the gastric emptying rate “for a prolonged period of” time. This result is an increased gastric retention time and a better control of the fluctuations in plasma drug concentration. The ultimate goal of any drug delivery is Effective disease / disorder management, minimum side effects and greater patient compliance in the cost effective manner. More than 50% of

the drug delivery systems available in the market are oral drug delivery systems. Controlled release drug delivery systems (CRDDS) provide drug release at a predetermined, predictable, and controlled rate. Controlled release drug delivery system is capable of achieving the benefits like maintenance of optimum therapeutic drug concentration in blood with predictable and reproducible release rates for extended time period, enhancement of “activity of duration for short” half-life drugs, elimination of side effects, “reducing frequency of dosing and” wastage of

drugs, optimized “therapy and better patient compliances. The” controlled “gastric retention of solid dosage” forms may be achieved by mucoadhesive systems that causes bioadhesion to stomach mucosa, floating systems, swelling and expanding systems, modified-shape systems, high density systems and other delayed gastric emptying devices. Gastro “retentive dosage form can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs”. Prolonged “gastric retention improves bioavailability, reduces drug waste, and” improves solubility of drugs that are “less soluble in a high pH environment. Gastro retention helps to provide better” availability of new products with suitable therapeutic activity and substantial benefits for patients.

**Drug name** : SOTALOL  
**Category** : Antiarrhythmic agents  
**CAS NO** : 3930-20-9  
**Structure** :




Fig.1

**Half-life:**

Mean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.

**Locust bean gum**

**Nonproprietary names:** carob gum, carob bean gum, carobin, E410

**Chemical Formula:** C<sub>27</sub>H<sub>42</sub>NO<sub>2</sub> Cl


**Structural Formula**

Fig.2

**Structure of locust bean gum**

**Molecular weight:** approximately 50,000-3,000,000

**Functional categories:** Locust bean gum can be used in gels, creams and lotions in hair and skin care applications. Thickening, Texture modifier, Stabilizer, Gel strengthener.

**Sodium Bicarbonate**

**Non-proprietary names:** BP/EP: sodium bicarbonate

**Synonym:** Baking soda, e-500, and monosodium carbonate.

**Chemical name:** carbonic acid, monosodium salt, monosodium carbonate.

**Empirical formula:** NaHCO<sub>3</sub>

**Molecular weight:** 84.01

**Category:** alkalinizing agent, therapeutic agent

**2. Methodology****Analytical method development:**

“Determination of absorption maxima:

A “solution containing the concentration 10 µg/ ml drug was prepared in 0.1N HCl UV spectrum was taken using Double beam UV/VIS spectrophotometer. The solution was scanned in the range of 200 – 400.

**Preparation” calibration curve:**

100mg of Sotalol pure “drug was dissolved in” 100ml” of “0.1N HCl (stock solution) 10ml of “solution was taken and make” up with 100ml of 0.1N HCl (100µg/ml). From “this 10ml was taken and” make “up with 100 ml of” 0.1N HCl (10µg/ml). The above solution “was subsequently diluted with 0.1N HCl to obtain” series of dilutions Containing 0.5,1, 1.5, 2 and 2.5µg/ml of Sotalol per ml “of solution. The absorbance of the above dilutions was measured” at 266 nm by using UV-Spectrophotometer “taking 0.1N HCl as blank. Then a graph was plotted by” taking “Concentration on X-Axis and Absorbance on Y-Axis which gives a straight line Linearity of standard curve was assessed from “the “square of correlation coefficient (R<sup>2</sup>)” which determined by least-square linear regression analysis.

**Formulation development “of Tablets:****Optimization of Sodium bicarbonate concentration:**

“Sodium bicarbonate was employed as” effervescent “gas generating agent. It helps the formulation to float. Various concentrations of sodium bicarbonate were employed; floating lag time and floating duration were observed. Based on that the concentration of sodium bicarbonate was finalized and” preceded for further formulations.

**Evaluation of post compression parameters for prepared Tablets**

The designed compression “tablets were studied for their physicochemical properties like weight variation, hardness”, thickness, friability and drug content.

**In vitro Buoyancy studies:**

The in “vitro buoyancy was determined by floating lag” time, and total floating time. (As “per the method described by” Rosa et al) The tablets were placed in a 100ml beaker containing 0.1N HCl. The time required for the “tablet to rise to the” surface “and float was determined as” floating “lag time (FLT) and duration of time the tablet constantly floats” on the dissolution medium was noted “as Total Floating Time respectively” (TFT).

**In vitro drug release studies****Dissolution” parameters:**

“Apparatus--USP-II, Paddle Method

Dissolution Medium -- 0.1 N HCl”

RPM --75

Sampling intervals (hrs)-- “0.5,1,2,3,4,5,6,7,8,10,11,12

Temperature --37°c ± 0.5°c

As the preparation was for floating drug release given through oral route of administration, different receptors fluids are used for evaluation the dissolution profile.

3. Results and Discussion




Figure 3: Standard graph of Sotalol in 0.1N HCl




Figure 4: FT-TR Spectrum of Sotalol pure drug




Figure 5: FT-IR Spectrum of Optimized Formulation




Figure 6: Dissolution profile of Sotalol floating tablets (ST1, ST2, ST3)




Figure 7: Dissolution profile of Sotalol floating tablets (ST4, ST5, ST6 ).




Figure 8: Dissolution profile of Sotalol floating tablets (ST7, ST8, ST9)




Figure 9: Zero order release kinetics




Figure 10: Higuchi release kinetic




Figure 11: First order release kinetics

**Table 1: Formulation composition for floating tablets**

Formulation No.	Sotalol	Methocel K 4 M	Locust Bean Gum	Xanthan gum	NaHCO <sub>3</sub>	Mag. Stearate	"Talc	MCC pH 102
ST1"	80	40	-----	-----	40	5	5	QS
ST2	80	60	-----	-----	40	5	5	QS
ST3	80	80	-----	-----	40	5	5	QS
ST4	80	-----	40	-----	40	5	5	QS
ST5	80	-----	60	-----	40	5	5	QS
ST6	80	-----	80	-----	40	5	5	QS
ST7	80	-----	-----	40	40	5	5	QS
ST8	80	-----	-----	60	40	5	5	QS
ST9	80	-----	-----	80	40	5	5	QS

**Table 2: Pre-formulation parameters of blend**

Formulation Code	Angle of Repose	Bulk density (gm/ml)	Tapped density (gm/ml)	Carr's index (%)	Hausner's Ratio
ST1	25.01	0.48	0.54	15.21	0.87
ST2	25.8	0.57	0.63	17.87	0.95
ST3	23.74	0.53	0.69	16.11	0.63
ST4	24.33	0.55	0.65	17.76	1.13
ST5	25.24	0.55	0.66	17.92	1.45
ST6	28.12	0.57	0.67	16.65	1.07
ST7	26.08	0.56	0.68	17.43	0.78
ST8	24.12	0.47	0.56	15.97	1.17
ST9	25.45	0.53	0.63	16.54	1.19

**Table 3: Dissolution Data of Sotalol Tablets Prepared With Methocel K 4M In Different Concentrations**

TIME (hr)	CUMULATIVE PERCENT DRUG RELEASED		
	ST1	ST2	ST3
0.5	8.77	13.14	10.21
1	18.51	24.16	22.8
2	24.4	29.77	28.21
3	27.14	33.47	34.11
4	33.11	37.64	38.45
5	37.97	43.97	47.21
6	42.97	47.12	52.77
7	47.79	51.77	58.34
8	53.77	53.74	64.77
9	54.94	59.44	73.64
10	62.87	65.32	80.54
11	68.77	75.11	83.11
12	84.22	82.21	97.45

#### 4. Conclusion

In the present research work gastro retentive floating matrix formulation of Sotalol by using various hydrophilic polymers. Among all the formulations the formulations prepared with HPMC K15 M retarded the drug release up to 12 hours in the concentration of 75 mg (ST3). The formulations prepared by using Xanthan gum were unable to produce desired drug release, they were unable to retard drug release up to 12 hours. The formulations prepared with Locust bean gum were also retarded the drug release

for more than 12 hours. Hence they were not considered. The optimized formulation dissolution data was subjected to release kinetics, from the release kinetics data it was evident that the formulation followed peppas mechanism of drug release.

#### 5. References

- [1] Harshal Soni, Chetan Ghulaxe, Surbhi Upadhyay, Sujit Pillai Development And In Vitro Evaluation Of

- An Oral Floating Tablet Of Metronidazole Journal of Drug Delivery & Therapeutics. 2018; 8(2):83-86
- [2] Athiya Nusrath , B.Deepika, K.Nagaraju, T.Regupathi, K.N.V Rao, K.Rajeswar Dutt Formulation And In Vitro Evaluation Of Cefpodoxime Proxetil Gastro Retentive Floating Tablets Innovat International Journal Of Medical & Pharmaceutical Sciences, 2017; 2(s1).
- [3] Afshan Meherose and G. Udaya Bhanu Formulation And In-Vitro Evaluation Of Floating Effervescent Tablets Of Ranitidine Hydrochloride IJPSR (2015), Vol. 6, Issue 12.
- [4] Mohammed Asif Hussain Mahender B Maimuna Anjum Formulation and Evaluation of effervescent floating matrix tablets of Ofloxacin Int. J. Drug Dev. & Res., January - March 2014, 6 (1): 188-198.
- [5] Rakesh Pahwa, Lovely Chhabra , Avneet Kaur Lamba , Sumit Jindal and Arvind Rathour Formulation and in-vitro evaluation of effervescent floating tablets of an antiulcer agent Journal of Chemical and Pharmaceutical Research, 2012, 4(2): 1066-1073.
- [6] Md. Haider Ali, Mohiuddin Ahmed Bhuiyan<sup>2</sup> , Md. Selim Reza<sup>3</sup> and Samira Karim<sup>1</sup> Formulation and In vitro Evaluation of Oral Floating Tablets of Salbutamol Sulphate: Comparison with Effervescent Tablets Dhaka Univ. J. Pharm. Sci. 15(2): 203-208, 2016.
- [7] C Haranath, J Raveendra Reddy, N Devanna. Formulation and In-Vitro Evaluation of Effervescent Floating Tablets of an Antibacterial Drug. Inventi Impact: Pharm Tech, 2016(4):145-151, 2016.
- [8] AkhlakAhmed, Narendra Kr. Goyal and Pramod K. Sharma Effervescent Floating Drug Delivery System: A Review Global Journal of Pharmacology 8 (4): 478-485, 2014.
- [9] Ali Raza, Nadeem Irfan Bukhari, Sabiha Karim y , Muhammad Ahsan Hafiz, Uzma Hayat Floating tablets of minocycline hydrochloride: Formulation, in-vitro evaluation and optimization Future Journal of Pharmaceutical Sciences 3 (2017) 131e139
- [1] K.Chaitanya, Sellappan Velmurugan Formulation And Evaluation Of Levodopa Effervescent Floating Tablets Int J Pharm Pharm Sci, Vol 7, Issue 5,189-193
- [2] Komuravelly Someshwar Kalyani Chithaluru, Tadikonda Ramarao K. K. Kalyan Kumar Formulation and evaluation of effervescent floating tablets of tizanidine hydrochloride Acta Pharm. 61 (2011) 217–226
- [3] Harsharan Pal Singh, Ashmeet Kaur , Ishpreet Kaur Formulation and evaluation of effervescent floating tablet of famotidine with natural polymer chitosan Asian Pac. J. Health Sci., 2014; 1(4): 517-523
- [4] R. Dawange, S. S. Khadabadi, S. S. Saboo Formulation and Evaluation of Floating Tablets of Verapamil Hydrochloride by using Gastroretentive Technology Int. J. Pharm. Sci. Rev. Res., 34(1), September – October 2015; Article No. 42, Pages: 263-269
- [5] Chordiya Mayur Ashok, Gangurde Hemant Hiranman , K . Senthilkumaran Formulation And In Vitro Evaluation Of Effervescent Floating Matrix Tablet Of Propafenone Hcl World Journal of Pharmacy and Pharmaceutical Sciences Volume 2, Issue 6, 5348-5362
- [6] Ajay Kumar, Ashni Verma,Geetika Sharma, Rupinder Saini, Shivani Sharma, Sukhdev Singh, Upendra K Jain, Mandeep Sharma Formulation and Characterization of Effervescent Floating Matrix Tablets of Famotidine Hydrochloride Asian Journal of Biomedical and Pharmaceutical Sciences; 3(25) 2013, 43-47.
- [7] Sarat Chandra Prasad Malisetty, Ravi Teja Allena, Swetha Sandina, HV Gangadharappa Formulation and evaluation of modified-release effervescent floating tablets of ofloxacin International Journal of Health & Allied Sciences, Vol. 2, Issue 2, Apr-Jun 2013.
- [8] Muhammad Imran, Nazar Muhammad Ranjha, Rao Khurram Ayoub Controlled-Release Low Density Effervescent Floating Matrix Tablets of Risperidone: Development, Optimization, in vitro-in vivo Evaluation in Healthy Human Volunteers and Determination of Dissolution Equivalency Iranian Journal of Pharmaceutical Sciences 2013: 9 (2): 31- 48
- [9] Venkata Srikanth Meka, Ambedkar Sunil Songa, Sreenivasa Rao Nali, Janaki Ram Battu and Venkata Ramana Murthy Kolapalli. Design and in vitro evaluation of effervescent gastric floating drug delivery systems of propranolol HCl. Invest Clin 53(1): 60-70, 2012
- [10] V. Kamalakanan , M. Karthikraja , K. Ravi , M. Kathikeyan , K. G.S.Arul kumran , A.Arunachalam Formulation and in-vitro evaluation of tinidazole effervescent floating tablets Journal of Pharmacy Research 2012,5(4),2321-2325
- [11] Chanchal Katariya, Anitha Roy<sup>2</sup> Floating Drug Delivery System for Analgesic - A Review Int. J. Pharm. Sci. Rev. Res., 43(2), March - April 2017; Article No. 01, Pages: 1-4
- [12] Srujana Katta, Mettu Srikanth Reddy, N. G. Raghavendra Rao Overview On Floating Drug Delivery System Am. J. PharmTech Res. 2013; 3(2)